Nasal Drug Delivery System-Factors Affecting and Applications

Jadhav, Kisan R.; Gambhire, M; Shaikh, Ishaque M.; Kadam, Vilarsrao J.; Pisal, Sambhaji S.

doi:10.2174/157488507779422374

Cited by 146 publications

(67 citation statements)

References 85 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nasal administration is significantly effective in case of oral administration of drug gives an undesirable side effect. From the pharmacokinetic standpoint, intranasal administration avoids first-pass metabolism and retards incomplete absorption in the gastrointestinal tract which leads to improve the bioavailability (Jadhav, 2007;Dey & Mahanti, 2011;Kushwaha et al, 2011).…”

Section: Introductionmentioning

confidence: 99%

Development ofin situgel for nasal delivery: design, optimization,in vitroandin vivoevaluation

2013

View full text Add to dashboard Cite

Context: The mucoadhesive gel formulations are helpful to prolong the residence time at the nasal absorption site and thereby facilitate the uptake of drug. Sumatriptan succinate has oral bioavailability of 15% and undergoes hepatic metabolism, hence it is suitable for nasal administration.Objective: The objective of the investigation was to develop a mucoadhesive in situ gel to improve the bioavailability of the sumatriptan succinate. Materials and methods: Deacetylated gellan gum was used as gelling agent. In situ gel was formulated by ion activation mechanism in simulated nasal fluid. A 3 2 factorial design was found suitable to optimize batch. In vivo study was carried out in Spraugue-Dawley rats, and drug was estimated in plasma by UPLC-MS. Result: The optimized batch showed drug release of 98.57% within 5 h followed by Peppas model of drug release. Ex vivo studies on sheep nasal mucosa showed 93.33% within 5 h. In histopathological study, optimized batch was found to be safe and stable in accelerated stability study for three months. Optimized formulation, F7 has shown absolute bioavailability, which was found to be 164.70%. Drug targeting index for brain tissues was found to be 1.866. Discussion: Concentration of the gelling polymer was compromised for satisfactory gel strength and an acceptable viscosity. The release depended on viscosity of formulation. Drug targeting index indicates sumatriptan can reach to brain via olfactory pathway. Conclusion: In situ gel proved to be suitable for administration of sumatriptan succinate through nasal route. The ease of administration coupled with less frequent administration enhances patient compliance.

show abstract

Section: Introductionmentioning

confidence: 99%

Development ofin situgel for nasal delivery: design, optimization,in vitroandin vivoevaluation

2013

View full text Add to dashboard Cite

show abstract

“…The benefits of nasal delivery [1] indicate that it is a good alternative to parenteral route, with its easy of administration (needle-free application). Thus, there is no need for trained personnel which means self-medication is possible; in addition, it does not contribute to biohazardous waste since special containers are not required [4,5].…”

Section: Benefits Of Nasal Deliverymentioning

confidence: 99%

“…Nasal administration of active molecules including peptide and proteins for systemic medication and immunization has been widely investigated in recent years. Benefits, limitations and absorption mechanism of nasal route from different points of view have also been evaluated by investigators [1][2][3][4]. Bioadhesive nasal drug delivery systems have been mostly designed as powders, micro-and nanoparticulate forms, hydrogels and inserts.…”

Section: Introductionmentioning

confidence: 99%

Nasal Inserts for Drug Delivery: An Overview

Algin-Yapar¹

2014

Trop. J. Pharm Res

View full text Add to dashboard Cite

show abstract

“…drug delivery is now recognized as a noninvasive route for CNS drugs and reliable alternative to oral and parenteral route (Pires et al, 2009). The nasal mucosa emerged as a target tissue for drug delivery and offers many benefits over the oral route due to its large surface area, high blood flow, porous endothelial membrane, avoidance of hepatic first pass metabolism and ready accessibility (Jadhav et al, 2007). A wide variety of therapeutic compounds can be administered intranasally for topical, systemic and CNS action (Pires et al, 2009).…”

Section: Introductionmentioning

confidence: 99%

“…The rapid absorption, fast onset of action due to relatively large absorption surface, high vascularization, avoidance of chemical and enzymatic degradation of drugs in the gastrointestinal (g.i.t) fluid, better permeability of lipophilic, low molecular weight drugs through nasal mucosa make this route for administration of drugs such as peptides or protein (Jadhav et al, 2007).…”

Section: Introductionmentioning

confidence: 99%

Insights into direct nose to brain delivery: current status and future perspective

et al. 2013

View full text Add to dashboard Cite

Now a day's intranasal (i.n) drug delivery is emerging as a reliable method to bypass the bloodbrain barrier (BBB) and deliver a wide range of therapeutic agents including both small and large molecules, growth factors, viral vectors and even stem cells to the brain and has shown therapeutic effects in both animals and humans. This route involves the olfactory or trigeminal nerve systems which initiate in the brain and terminate in the nasal cavity at the olfactory neuroepithelium or respiratory epithelium. They are the only externally exposed portions of the central nervous system (CNS) and therefore represent the most direct method of noninvasive entry into the brain. This approach has been primarily used to explore therapeutic avenues for neurological diseases. The potential for treatment possibilities with olfactory transfer of drugs will increase as more effective formulations and delivery devices are developed. Recently, the apomorphine hydrochloride dry powders have been developed for i.n. delivery (Apomorphine nasal, Lyonase technology, Britannia Pharmaceuticals, Surrey, UK). The results of clinical trial Phase III suggested that the prepared formulation had clinical effect equivalent to subcutaneously administered apomorphine. In coming years, intranasal delivery of drugs will demand more complex and automated delivery devices to ensure accurate and repeatable dosing. Thus, new efforts are needed to make this noninvasive route of delivery more efficient and popular, and it is also predicted that in future a range of intranasal products will be used in diagnosis as well as treatment of CNS diseases. This review will embark the existing evidence of nose-to-brain transport. It also provides insights into the most relevant pre-clinical studies of direct nose-brain delivery and delivery devices which will provide relative success of intranasal delivery system. We have, herein, outlined the relevant aspects of CNS drugs given intranasally to direct the brain in treating CNS disorders like Alzheimer's disease, depression, migraine, schizophrenia, etc.

show abstract

Nasal Drug Delivery System-Factors Affecting and Applications

Cited by 146 publications

References 85 publications

Development ofin situgel for nasal delivery: design, optimization,in vitroandin vivoevaluation

Development ofin situgel for nasal delivery: design, optimization,in vitroandin vivoevaluation

Nasal Inserts for Drug Delivery: An Overview

Insights into direct nose to brain delivery: current status and future perspective

Contact Info

Product

Resources

About